Cart
sales@molnova.com
MK-5108
CAS No. 1010085-13-8
MK-5108( MK 5108 | VX-689 | VX 689 | MK5108 | VX689 )
Catalog No. M10067 CAS No. 1010085-13-8
MK-5108 (VX-689) is a potent, highly selective Aurora-A kinase inhibitor with IC50 of 0.064 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 72 | In Stock |
|
| 10MG | 125 | In Stock |
|
| 25MG | 215 | In Stock |
|
| 50MG | 335 | In Stock |
|
| 100MG | 500 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMK-5108
-
NoteResearch use only, not for human use.
-
Brief DescriptionMK-5108 (VX-689) is a potent, highly selective Aurora-A kinase inhibitor with IC50 of 0.064 nM.
-
DescriptionMK-5108 (VX-689) is a potent, highly selective Aurora-A kinase inhibitor with IC50 of 0.064 nM, displays robust selectivity against Aurora-B (220-fold) and Aurora-C (190-fold) in the biochemical assays; also exhibits high selectivity for Aurora-A over a panel of 233 kinases, only one kinase (TrkA) with <100-fold selectivity; inhibits the growth of multiple human cancer cell lines in vitro and in human cancer xenograft models; MK-5108 significantly enhanced the efficacy of docetaxel without increasing its toxicity.Solid Tumors Phase 1 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsMK 5108 | VX-689 | VX 689 | MK5108 | VX689
-
PathwayCell Cycle/DNA Damage
-
TargetAurora Kinase
-
RecptorAuroraA
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1010085-13-8
-
Formula Weight461.94
-
Molecular FormulaC22H21ClFN3O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 6.4 mg/mL (Need Warming)
-
SMILESOC(=O)[C@@]1(CC2=CC=CC(NC3=NC=CS3)=N2)CC[C@@H](CC1)OC1=C(F)C(Cl)=CC=C1 |r,c:7,13,16,26,30,32,t:5,11|
-
Chemical NameCyclohexanecarboxylic acid, 4-(3-chloro-2-fluorophenoxy)-1-[[6-(2-thiazolylamino)-2-pyridinyl]methyl]-, trans-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shimomura T, et al. Mol Cancer Ther. 2010 Jan;9(1):157-66.
2. Kretzner L, et al. Cancer Res. 2011 Jun 1;71(11):3912-20.
3. Shan W, et al. Clin Cancer Res. 2012 Jun 15;18(12):3352-65.
4. Chefetz I, et al. Cell Cycle. 2011 Jul 1;10(13):2206-14.
molnova catalog
related products
-
GSK-1070916
A potent, selective and ATP-competitive inhibitor of Aurora B and C with Ki of 0.38 nM and 1.5 nM, respectively.
-
SA 16
A potent, dual PDK1 and Aurora kinase A inhibitor with IC50 of 416 and 35 nM, respectively.
-
Raddeanin A
Raddeanin A has moderate inhibitory activity against histone deacetylases (HDACs). Raddeanin A has high antiangiogenic potency, antitumor activity.
